Empliciti (Elotuzumab

• Empliciti is the first monoclonal antibody that targets the signaling lymphocytic activation molecule family (SLAMF) 7 protein, and the second monoclonal antibody used
  
• in combination with medicines lenalidomide and dexamethasone for the treatment of adults with multiple myeloma (MM) who have received 1 to 3 prior therapies.
  
• in combination with medicines pomalidomide and dexamethasone for the treatment of adults with multiple myeloma (MM) who have received at least prior therapies including lenalidomide and a proteasome inhibitor (PI). 

Recommended Dosage: 

With lenalidomide and dexamethasone: The recommended dose of Empliciti is 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter until disease progression or unacceptable toxicity.

With pomalidomide and dexamethasone: The recommended dose is 10 mg/kg intravenously (IV) given every week for the initial two cycles and 20 mg/kg every four weeks thereafter until disease progression or unacceptable toxicity.

• Elotuzumab can cause infusion reactions. The most common symptoms of an infusion reaction include chills, fever, and hypertension. Hypotension and bradycardia are also developed during infusions. Interrupt infusion for Grade 2 or higher infusion reactions and institute apt medical management.
  
• Invasive second primary malignancies (SPM) may develop in those treated with Ld, those treated with Pd and in none of those treated with E-Pd. Monitor all the patients for the establishment of second primary malignancies.
  
• An increase in liver enzymes consistent with hepatotoxicity may develop in those treated with E-Ld and Ld. Monitor liver enzymes periodically. Discontinue treatment upon Grade 3 or higher increase in liver enzymes. After the return to baseline values, continuation of therapy may be considered.  
  
• Empliciti is a humanized IgG kappa monoclonal antibody that can be responsible for interfering with assays considered to monitor M-protein. This interference can affect the determination of complete response (CR). 

What documents are required to import EMPLICITI to India?

EMPLICITI (elotuzumab) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

EMPLICITI (elotuzumab injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Empliciti in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of EMPLICITI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Empliciti 300 mg/400 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the EMPLICITI (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Empliciti ®?

Elotuzumab is a Generic Name for the trade name drug Empliciti®.

What is the Manufacturer’s Name of Empliciti ®?

Empliciti® is manufactured by Bristol-Myers Squibb.

Is Empliciti® approved by the FDA?

Yes, Empliciti® is approved by the FDA. Date of first/initial approval: November 30, 2015.

What is the dosage and form of Empliciti® supplied?

Empliciti® is supplied as Injections: 300 mg or 400 mg lyophilized powder in a single-dose vial for intravenous use. 

What are the most common side effects of Empliciti®? 

The most common side effects of Empliciti:

with lenalidomide and dexamethasone are decreased appetite, fatigue, cough, diarrhea, pyrexia, peripheral neuropathy, constipation, nasopharyngitis, upper respiratory tract infection, and pneumonia.

with pomalidomide and dexamethasone are hyperglycemia and constipation.

How much does Empliciti® cost in India?

The cost of Empliciti in India can vary. To procure this SLAMF7-directed immunostimulatory antibody legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Empliciti®?

Store under refrigeration at 2°C to 8°C (36°F to 46°F). Protect it from the light by storing in the original package until time of use. Never freeze or shake it. 

Is it safe to buy Empliciti® online in India?

Yes, one can buy Empliciti online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Empliciti® through legal channels.